Skip to content
Medical Health Aged Care

New report on Australia’s health reinforces need for increased investment in dementia services, awareness raising and brain health promotion

Dementia Australia 2 mins read

Dementia is the second leading cause of death in Australia, the leading cause of death of women, the second leading cause of disease burden overall, and the leading cause of burden for people aged 65 as reported by the Australian Institute of Health and Welfare (AIHW) in Australia’s Health 2024 publication released today.

Dementia Australia CEO Professor Tanya Buchanan said the report reinforces the enormity and impact of dementia in Australia as the chronic disease of the 21st century and must receive the attention it needs.

“The report provides vital information for governments, and the health, aged care and disability sectors to ensure there is investment in appropriate dementia supports and services,” Professor Buchanan said.
 
“The data also provides compelling evidence of the need for further funding commitments to dementia research, increasing community awareness and a strategic public health approach to dementia prevention.
 
“The latest research tells us that with increased awareness of the modifiable risk factors across populations and over time, we could be delaying or potentially preventing 40 per cent of dementia cases.
 
“With the number of people with dementia expected to double by 2054, we need a National Dementia Action Plan to provide a clear vision for the future to move dementia care forward in Australia.   
 
“Dementia Australia and people living with dementia, their families and carers have contributed to the development of the next iteration of the draft National Dementia Action Plan and we eagerly await its release.
 
“With more than 421,000 people living with dementia in Australia, and more than 1.6 million people involved in their care it is essential that all Australians know that no matter who you are or how you’re affected by dementia, Dementia Australia is here for you. 
 
“I encourage anyone with any questions or concerns to contact the National Dementia Helpline on 1800 100 500, 24 hours a day, seven days a week or visit dementia.org.au.” 

-Ends-

Dementia Australia is the source of trusted information, education and services for the estimated more than 421,000 Australians living with dementia, and the more than 1.6 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

Media contacts: Gabrielle Prabhu, Media & Communications Manager, 0447 253 583 or [email protected]

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au. 

Media

More from this category

  • Finance Investment, Medical Health Aged Care
  • 16/04/2026
  • 15:21
JMM

BlinkLab Secures A$17.5M to Advance FDA Trial and Commercial Launch of AI-Powered Autism Diagnostic, Expands ADHD Program

BlinkLab Limited (ASX: BB1) a digital healthcare company developing AI-powered diagnostic technologies, has secured A$17.5 million in an oversubscribed placement to institutional and sophisticated investors, positioning the Company to accelerate regulatory milestones and commercialisation of its lead autism diagnostic platform while expanding into the significantly larger ADHD market. The capital raise, priced at A$0.65 per share, marks a critical inflection point for BlinkLab as it advances toward FDA approval and market entry for BlinkLab Dx1, its smartphone-based diagnostic aid for autism. Funding to Accelerate Regulatory Pathway and Commercial Readiness Proceeds from the placement will be deployed across key value-driving initiatives,…

  • Contains:
  • Medical Health Aged Care
  • 16/04/2026
  • 15:11
Galderma

Galderma Launches New Alastin Regenerating Skin Nectar with TriHex+(TM), Powered by Its Next-Generation TriHex Technology® Regenerative Platform

Regenerating Skin Nectar has long played a central role in the peri-procedural skin journey as part of Alastin’s dedicated procedure support portfolio, enhancing the…

  • Contains:
  • Medical Health Aged Care
  • 16/04/2026
  • 14:37
Palliative Care Australia

National Palliative Care Week 2026 urges Australians to ask the big questions

Key Facts: · More than 450 people in Australia die each day of a life-limiting illness and could benefit from palliative care. · Dementia is now the leading cause of death in Australia, accounting for 9.4% of all deaths in 2024. · Only 38% of people who die of a life-limiting illness receive specialist palliative care. On average, people first receive specialist palliative care 15 days before death, and only 1 in 5 people receive timely palliative care (three months or more before death). · 73% of Australians say they are open to talking about advance care planning, but only…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.